Cognitive changes in multiple sclerosis and factors of their development: association with taking disease-modifying therapies

Currently, there is an increase in the life expectancy of patients with multiple sclerosis (MS) due to the improvement of their medical care and the use of disease-modifying therapies (DMTs). Due to the increase in life expectancy, the problem of cognitive impairment (CI) in MS patients becomes relevant. It has been shown that the risk of developing Alzheimer's disease in MS patients aged 45 to 64 years is 4–6 times higher than in the general population. The main non-modifiable risk factors for CI in MS are carriage of HLA-DRB1*15:01, PSEN1, PSEN2, APP, APOE ε4 genes, old age (60 years and older), male gender, prolonged course of the disease, high degree of disability according to EDSS. Modifiable risk factors for CI in MS patients are high levels of anxiety and depression, presence of diabetes mellitus, vascular risk factors, smoking, and drug use. The protective factors for MS include the use of DMTs, high cognitive reserve, high level of physical and social activity.

1. Hauser SL, Cree BAC. Treatment of Multiple Sclerosis: A Review. Am J Med. 2020 Dec;133(12):1380-90. doi: 10.1016/j.amjmed.2020.05.049

2. Maiese K. Cognitive Impairment in Multiple Sclerosis. Bioengineering (Basel). 2023 Jul 23;10(7):871. doi: 10.3390/bioengineering10070871

3. Shmidt TE. Dimethyl fumarate (tecfidera) is a first-line drug of choice for the treatment of remitting multiple sclerosis. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2017;117(11):140-5. doi: 10.17116/jnevro2017117111140-145 (In Russ.).

4. Portaccio E, Magyari M, Havrdova EK, et al. Multiple sclerosis: emerging epidemiological trends and redefining the clinical course. Lancet Reg Health Eur. 2024 Aug;22(44):100977. doi: 10.1016/j.lanepe.2024.100977

5. Margoni M, Preziosa P, Rocca MA, Filippi M. Depressive symptoms, anxiety and cognitive impairment: emerging evidence in multiple sclerosis. Transl Psychiatry. 2023 Jul 19;13(1):264. doi: 10.1038/s41398-023-02555-7

6. Zakharov VV. Introduction to behavioral neurology. Povedencheskaya nevrologiya = Behavioral Neuroscience. 2021;(1):8-17. doi: 10.46393/2712-9675_2021_1_8-16 (In Russ.).

7. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Diseases. Fifth Edition. (DSM-V). London; 2013. Available at: https://www.psychiatry.org/psychiatrists/practice/dsm

8. Baysal Kirac L, Ekmekci Ö, Yüceyar N, Sagduyu Kocaman A. Assessment of early cognitive impairment in patients with clinically isolated syndromes and multiple sclerosis. Behav Neurol. 2014;2014:637694. doi: 10.1155/2014/637694. Epub 2014 Apr 14.

9. Zimagullova OYu. Disorders of mental processes in patients with multiple sclerosis. Mediko-sotsial'nye problemy invalidnosti = Medical and Social Problems of Disability. 2014;(1):26-30 (In Russ.).

10. Benedict RHB, Amato MP, DeLuca J, Geurts JJG. Cognitive impairment in multiple sclerosis: clinical management, MRI, and therapeutic avenues. Lancet Neurol. 2020 Oct;19(10):860-71. doi: 10.1016/S14744422(20)30277-5. Epub 2020 Sep 16.

11. Macias Islas MA, Ciampi E. Assessment and Impact of Cognitive Impairment in Multiple Sclerosis: An Overview. Biomedicines. 2019 Mar 19;7(1):22. doi: 10.3390/biomedicines7010022

12. Oreja-Guevara C, Ayuso Blanco T, Brieva Ruiz L, et al. Cognitive Dysfunctions and Assessments in Multiple Sclerosis. Front Neurol. 2019 Jun 4;10:581. doi: 10.3389/fneur.2019.00581

13. Piacentini C, Argento O, Nocentini U. Cognitive impairment in multiple sclerosis: "classic" knowledge and recent acquisitions. Arq Neuropsiquiatr. 2023 Jun;81(6):585-96. doi: 10.1055/s-0043-1763485

14. Sehanovic A, Smajlovic D, Tupkovic E, et al. Cognitive Disorders in Patients with Multiple Sclerosis. Mater Sociomed. 2020 Sep;32(3):191-5. doi: 10.5455/msm.2020.32.191-195

15. Lugosi K, Engh MA, Huszаr Z, et al. Domain-specific cognitive impairment in multiple sclerosis: A systematic review and meta-analysis. Ann Clin Transl Neurol. 2024 Mar;11(3):564-76. doi: 10.1002/acn3.51976

16. Henry A, Tourbah A, Chaunu MP, et al. Social cognition impairments in relapsingremitting multiple sclerosis. J Int Neuropsychol Soc. 2011 Nov;17(6):1122-31. doi: 10.1017/S1355617711001147

17. Dulau C, Deloire M, Diaz H, et al. Social cognition according to cognitive impairment in different clinical phenotypes of multiple sclerosis. J Neurol. 2017 Apr;264(4):740-8. doi: 10.1007/s00415-017-8417-z

18. Cho EB, Jung SY, Jung JH, et al. The risk of dementia in multiple sclerosis and neuromyelitis optica spectrum disorder. Front Neurosci. 2023 Jun;15;17:1214652. doi: 10.3389/fnins.2023.1214652

19. Mahmoudi E, Sadaghiyani S, Lin P, et al. Diagnosis of Alzheimer's disease and related dementia among people with multiple sclerosis: Large cohort study, USA. Mult Scler Relat Disord. 2022 Jan;57:103351. doi: 10.1016/j.msard.2021.103351

20. Oset M, Stasiolek M, Matysiak M. Cognitive Dysfunction in the Early Stages of Multiple Sclerosis – How Much and How Important? Curr Neurol Neurosci Rep. 2020 May 22;20(7):22. doi: 10.1007/s11910-020-01045-3

21. Tremblay A, Charest K, Brando E, et al. The effects of aging and disease duration on cognition in multiple sclerosis. Brain Cogn. 2020 Dec;146:105650. doi: 10.1016/j.bandc.2020.105650

22. Hecker M, Bühring J, Fitzner B, et al. Genetic, Environmental and Lifestyle Determinants of Accelerated Telomere Attrition as Contributors to Risk and Severity of Multiple Sclerosis. Biomolecules. 2021 Oct;13;11(10):1510. doi: 10.3390/biom11101510

23. Ruano L, Portaccio E, Goretti B, et al. Age and disability drive cognitive impairment in multiple sclerosis across disease subtypes. Mult Scler. 2017 Aug;23(9):1258-67. doi: 10.1177/1352458516674367

24. Sepulveda-Falla D, Velez JI, Acosta-Baena N, et al. Genetic modifiers of cognitive decline in PSEN1 E280A Alzheimer's disease. Alzheimers Dement. 2024 Apr;20(4):2873-85. doi: 10.1002/alz.13754

25. Bagaria J, Bagyinszky E, An SSA. Genetics, Functions, and Clinical Impact of Presenilin-1 (PSEN1) Gene. Int J Mol Sci. 2022 Sep;19;23(18):10970. doi: 10.3390/ijms231810970

26. Koberskaya NN. Alzheimer's disease. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2019;11(S3):52-60. doi: 10.14412/2074-2711-2019-3S-52-60 (In Russ.).

27. Ritchie SJ, Hill WD, Marioni RE, et al. Polygenic predictors of age-related decline in cognitive ability. Mol Psychiatry. 2020 Oct;25(10):2584-98. doi: 10.1038/s41380-0190372-x

28. Sadigh-Eteghad S, Abbasi Garravnd N, Feizollahi M, Talebi M. The Expanded Disability Status Scale Score and Demographic Indexes Are Correlated with the Severity of Cognitive Impairment in Multiple Sclerosis Patients. J Clin Neurol. 2021 Jan;17(1):113-20. doi: 10.3988/jcn.2021.17.1.113

29. Elkhooly M, Bao F, Raghib M, et al. Role of white matter in cognitive impairment among relapsing remitting multiple sclerosis patients. Mult Scler Relat Disord. 2023 Nov;79:105030. doi: 10.1016/j.msard.2023.105030. Epub 2023 Oct 5.

30. Marrie RA, Patel R, Figley CR, et al. Diabetes and anxiety adversely affect cognition in multiple sclerosis. Mult Scler Relat Disord. 2019 Jan;27:164-70. doi: 10.1016/j.msard.2018.10.018. Epub 2018 Oct 23.

31. Van Ballegooijen H, van der Hiele K, Enzinger C, et al. The longitudinal relationship between fatigue, depression, anxiety, disability, and adherence with cognitive status in patients with early multiple sclerosis treated with interferon beta-1a. eNeurologicalSci. 2022 Jun;14;28:100409. doi: 10.1016/j.ensci.2022.100409

32. Alshehri E, Cohen JA, Ontaneda D, et al. The impact of cigarette smoking on cognitive processing speed and brain atrophy in multiple sclerosis. Mult Scler. 2023 Jun;29(7):846-55. doi: 10.1177/13524585231172490

33. Honarmand K, Tierney MC, O'Connor P, Feinstein A. Effects of cannabis on cognitive function in patients with multiple sclerosis. Neurology. 2011 Mar;29;76(13):1153-60. doi: 10.1212/WNL.0b013e318212ab0c

34. Virgilio E, Vecchio D, Crespi I, et al. Serum Vitamin D as a Marker of Impaired Information Processing Speed and Early Disability in Multiple Sclerosis Patients. Brain Sci. 2021 Nov 17;11(11):1521. doi: 10.3390/brainsci11111521

35. McNicholas N, Russell A, Nolan G, et al. Impact of obstructive sleep apnoea on cognitive function in multiple sclerosis: A longitudinal study. J Sleep Res. 2021 Jun;30(3):e13159. doi: 10.1111/jsr.13159

36. Fitzgerald KC, Damian A, Conway D, Mowry EM. Vascular comorbidity is associated with lower brain volumes and lower neuroperformance in a large multiple sclerosis cohort. Mult Scler. 2021 Oct;27(12):1914-23. doi: 10.1177/1352458520984746

37. Artemiadis A, Bakirtzis C, Ifantopoulou P, et al. The role of cognitive reserve in multiple sclerosis: A cross-sectional study in 526 patients. Mult Scler Relat Disord. 2020 Jun;41:102047. doi: 10.1016/j.msard.2020.102047

38. Motl RW, Sandroff BM, Benedict RHB. Moderate-to-vigorous physical activity is associated with processing speed, but not learning and memory, in cognitively impaired persons with multiple sclerosis. Mult Scler Relat Disord. 2022 Jul;63:103833. doi: 10.1016/j.msard.2022.103833

39. Motl RW, Gappmaier E, Nelson K, Benedict RH. Physical activity and cognitive function in multiple sclerosis. J Sport Exerc Psychol. 2011 Oct;33(5):734-41. doi: 10.1123/jsep.33.5.734

40. Kever A, Buyukturkoglu K, Riley CS, et al. Social support is linked to mental health, quality of life, and motor function in multiple sclerosis. J Neurol. 2021 May;268(5):1827-36. doi: 10.1007/s00415-020-10330-7

41. Landmeyer NC, Bürkner PC, Wiendl H, et al. Disease-modifying treatments and cognition in relapsing-remitting multiple sclerosis: A meta-analysis. Neurology. 2020 Jun 2;94(22):e2373-e2383. doi: 10.1212/WNL.0000000000009522

42. Schoonheim MM, Popescu V, Rueda Lopes FC, et al. Subcortical atrophy and cognition: sex effects in multiple sclerosis. Neurology. 2012 Oct 23;79(17):1754-61. doi: 10.1212/WNL.0b013e3182703f46

43. Naseri A, Baghernezhad K, Seyedi-Sahebari S, et al. The association of apolipoprotein E (ApoE) genotype and cognitive outcomes in multiple sclerosis; a systematic review and meta-analysis. Mult Scler Relat Disord. 2022 Sep;65:104011. doi: 10.1016/j.msard.2022.104011

44. Sbardella E, Petsas N, Tona F, et al. Assessing the correlation between grey and white matter damage with motor and cognitive impairment in multiple sclerosis patients. PLoS One. 2013 May;16;8(5):e63250. doi: 10.1371/journal.pone.0063250

45. Goretti B, Viterbo RG, Portaccio E, et al. Anxiety state affects information processing speed in patients with multiple sclerosis. Neurol Sci. 2014 Apr;35(4):559-63. doi: 10.1007/s10072-013-1544-0

46. Ozcan ME, Ince B, Bingöl A, et al. Association between smoking and cognitive impairment in multiple sclerosis. Neuropsychiatr Dis Treat. 2014 Sep;10;10:1715-9. doi: 10.2147/NDT.S68389

47. Giedraitiene N, Taluntiene V, Kaubrys G. Relationship between cognition and treatment adherence to disease-modifying therapy in multiple sclerosis: a prospective, cross-sectional study. Sci Rep. 2022 Jul;20;12(1):12447. doi: 10.1038/s41598-02216790-3

48. Desai P, Dhana K, DeCarli C, et al. Examination of Neurofilament Light Chain Serum Concentrations, Physical Activity, and Cognitive Decline in Older Adults. JAMA Netw Open. 2022 Mar;1;5(3):e223596. doi: 10.1001/jamanetworkopen.2022.3596

49. Claflin SB, Broadley S, Taylor BV. The Effect of Disease Modifying Therapies on Disability Progression in Multiple Sclerosis: A Systematic Overview of Meta-Analyses. Front Neurol. 2019 Jan;10;9:1150. doi: 10.3389/fneur.2018.01150

50. Patti F, Morra VB, Amato MP, et al. Subcutaneous interferon β-1a may protect against cognitive impairment in patients with relapsing-remitting multiple sclerosis: 5-year follow-up of the COGIMUS study. PLoS One. 2013 Aug;30;8(8):e74111. doi: 10.1371/journal.pone.0074111

51. Ziemssen T, Bajenaru OA, Carra A, et al. A 2-year observational study of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate from other disease-modifying therapies: the COPTIMIZE trial. J Neurol. 2014 Nov;261(11):2101-11. doi: 10.1007/s00415-014-7446-0. Epub 2014 Aug 14. Erratum in: J Neurol. 2015 Jan;262(1):248. doi: 10.1007/s00415-014-7565-7

52. Amato MP, Goretti B, Brescia Morra V, et al. Effects of 2-year treatment with dimethyl fumarate on cognition and functional impairment in patients with relapsing remitting multiple sclerosis. Neurol Sci. 2020 Nov;41(11):3185-93. doi: 10.1007/s10072-020-04320-w. Epub 2020 May 1.

53. Weinstock-Guttman B, Galetta SL, Giovannoni G, et al. Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS. J Neurol. 2012 May;259(5):898-905. doi: 10.1007/s00415-0116275-7

54. Benedict R, Penner IK, Cutter G, et al. Improvement in Cognitive Processing Speed With Ofatumumab in Patients With Relapsing Multiple Sclerosis (P6-3.005). Neurology. 2023 Apr;100(17):3344. doi: 10.1212/WNL.0000000000203201

55. Cohan S, Benedict R, Seze JD, et al. Time to cognitive worsening in patients with relapsing multiple sclerosis in ocrelizumab phase III trials (S44.005). Neurology. 2018 Apr;90(15):S44.005. doi: 10.1212/WNL.90.15_supplement.S44.005

56. Comi G, Patti F, Rocca MA, et al. Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsingremitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study). J Neurol. 2017 Dec;264(12):2436-449. doi: 10.1007/s00415-017-8642-5

57. Ngandu T, Lehtisalo J, Solomon A, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet. 2015 Jun;6;385(9984):2255-63. doi: 10.1016/S01406736(15)60461-5

58. Zakharov VV, Lokshina AB, Vakhnina NV. Combined therapy for Alzheimer's disease. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2022;14(3):74-80. doi: 10.14412/2074-2711-2022-3-74-80 (In Russ.).

59. Parfenov VA, Grishina DA, Tyurina AYu. Alzheimer's disease: diagnosis and treatment, errors in patient management. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2024;16(2):95-100. doi: 10.14412/2074-2711-2024-2-95-100 (In Russ.).